Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

Patients with vitiligo are often told nothing can be done, but even severe disease is potentially treatable, a recent ...

Dec 19 (Reuters) - Merck's (MRK.N), opens new tab experimental two-drug combination met the main goal of significantly ... However, the treatment was not superior to Biktarvy in suppressing ...

The treatment's safety was consistent with prior clinical studies, the company said. The therapy also helped improve survival rates over time, according to Novocure. The rate of overall survival ...